Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27341 | 0.94 | MAPT (0.37) | MAPTPOLBAPEX1TDP1MEN1 | |
| SCHEMBL22390581 | 0.94 | MAPT (0.37) | MAPTPOLBAPEX1TDP1MEN1 | |
| SCHEMBL5585363 | 0.94 | MAPT (0.37) | MAPTPOLBAPEX1TDP1MEN1 | |
| Hydrochloric Acid SCHEMBL10904239 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 | |
| Bromide SCHEMBL8064378 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 | |
| Bromide SCHEMBL7615302 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 | |
| Hydrochloric Acid SCHEMBL3839089 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 | |
| Iodide SCHEMBL8077383 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 | |
| SCHEMBL16207394 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 | |
| SCHEMBL9796698 | 0.92 | MAPT (0.36) | MAPTPOLBAPEX1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024127365-A1 | STABLE PHARMACEUTICAL COMPOSITION OF AN AMINE DRUG | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2024-06-20 | — | — | WO | claimed |
| US-20230364022-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | VICORE PHARMA AB (SE) | 2023-11-16 | — | — | US | claimed |
| US-20230293444-A1 | NEW PHARMACEUTICAL COMPOSITIONS | CALLIDITAS THERAPEUTICS AB (SE) | 2023-09-21 | — | — | US | claimed |
| EP-4218737-A1 | NEW DELAYED RELEASE COMPOSITION FOR PERORAL ADMINISTRATION | Vicore Pharma AB (SE) | 2023-08-02 | — | — | EP | claimed |
| WO-2023139285-A1 | PHARMACEUTICAL COMPOSITION COMPRISING BUDESONIDE FOR TREATING IGA NEPHROPATHY | CALLIDITAS THERAPEUTICS AB (SE) | 2023-07-27 | — | — | WO | claimed |
| CN-113647993-B | Noninvasive intestinal component collection capsule and application method thereof | 成都医学院 | 2023-06-16 | — | — | CN | claimed |
| US-11654115-B2 | Delayed release composition for peroral administration | VICORE PHARMA AB (SE) | 2023-05-23 | — | — | US | claimed |
| US-20220054452-A1 | DULOXETINE SPRINKLES | SUN PHARMACEUTICAL IND LTD (IN) | 2022-02-24 | — | — | US | claimed |
| US-11202772-B2 | Duloxetine sprinkles | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2021-12-21 | — | — | US | claimed |
| CN-113647993-A | Noninvasive intestinal component collection capsule and using method thereof | 成都医学院 | 2021-11-16 | — | — | CN | claimed |
| US-5229131-A | Divided dosage | UNIVERSITY OF MICHIGAN (US) | 1993-07-20 | — | — | US | claimed |
| US-5171580-A | Spray coating the core with three protective layers of anionic acrylic copolymer, gel-forming modified cellulose polymer and outer layer of gastroresistant polymer; antiinflammatory agent corticoid, antibiotic, peptides, protein and antitumor agent | BOEHRINGER INGELHEIM ITALIA S.P.A. (IT) | 1992-12-15 | — | — | US | claimed |
| EP-0239361-B1 | SUSTAINED-RELEASE PHARMACEUTICAL PREPARATION | KINAFORM TECHNOLOGY, INC. (US) | 1992-12-02 | — | — | EP | claimed |
| US-5102668-A | Polymer membrane or matrix of microparticles | KINGAFORM TECHNOLOGY, INC. (US) | 1992-04-07 | — | — | US | claimed |
| US-5026559-A | Multilayer walled coating | KINAFORM TECHNOLOGY, INC. (US) | 1991-06-25 | — | — | US | claimed |
| EP-0425659-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS HAVING pH CONTROLLED MEMBRANE COATINGS. | KINAFORM TECHNOLOGY INC (US) | 1991-05-08 | — | — | EP | claimed |
| US-4983401-A | Sustained release pharmaceutical preparations having pH controlled membrane coatings | KINAFORM TECHNOLOGY, INC. (US) | 1991-01-08 | — | — | US | claimed |
| WO-1990014077-A1 | SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS HAVING pH CONTROLLED MEMBRANE COATINGS | KINAFORM TECHNOLOGY, INC. (US) | 1990-11-29 | — | — | WO | claimed |
| EP-0391518-A2 | Sustained-release pharmaceutical preparation | KINAFORM TECHNOLOGY, INC. (US) | 1990-10-10 | — | — | EP | claimed |
| EP-0239361-A1 | Sustained-release pharmaceutical preparation | KINAFORM TECHNOLOGY, INC. (US) | 1987-09-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293444-A1 | NEW PHARMACEUTICAL COMPOSITIONS | PDCD2L, PGA5, PDE12 | MAPT 1276/4885POLB 4429/4885APEX1 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.